Article
POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jul 2015
van Gool Inge C, Eggink Florine A, Freeman-Mills Luke, Stelloo Ellen, Marchi Emanuele, de Bruyn Marco, Palles Claire, Nout Remi A, de Kroon Cor D, Osse Elisabeth M, Klenerman Paul, Creutzberg Carien L, Tomlinson Ian Pm, Smit Vincent Thbm, Nijman Hans W, Bosse Tjalling, Church David N
Abstract excerpt
PURPOSE: Recent studies have shown that 7% to 12% of endometrial cancers are ultramutated due to somatic mutation in the proofreading exonuclease domain of the DNA replicase POLE. Interestingly, these tumors have an excellent prognosis. In view of the emerging data linking mutation burden, immune response, and clinical outcome in cancer, we investigated whether POLE-mutant endometrial cancers showed evidence of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.